“We are impressed with the innovation and potential of MIM Fertility and their commitment to addressing real-world issues in reproductive health,” emphasizes Piotr Pietrzak of Tangent Line Ventures. “Their approach to applying artificial intelligence to improve infertility treatment outcomes is exactly what modern medicine needs.”
With great excitement, we want to share the news that we have just completed our Seed funding round, securing an impressive 2 million USD from Tangent Line Ventures and Peleton. This is not just significant financial support but also a sign of trust in our mission and the innovation of the MIM Fertility. 🌟💫
MIM Fertility is our answer to the challenges associated with infertility treatment – we combine advanced AI technologies with reproductive medicine to open new doors for couples around the world. Our cutting-edge AI-powered software platforms, EMBRYOAID and FOLLISCAN, represent the most effective and innovative solutions when it comes to the identification and analysis of ovarian follicles and embryo quality assessment. 🧬🔍
Thanks to this investment, we will be able to further refine our technologies, develop new functionalities, and expand our presence in international markets. This is a significant step towards realizing our mission: empowering fertility professionals with AI tools that support them to fulfill every couple’s dream of parenthood. 👶💞
Our heartfelt thanks to our investors for their support and trust in our TEAM and our mission.
More info about Tangent Line Ventures:
#MIMFertility #AIinMedicine #HealthcareInnovation #SeedFunding #FutureOfInfertilityTreatment